Christian S. Alvarez, Barry I. Graubard, Jake E. Thistle, Jessica L. Petrick, Katherine A. McGlynn – 16 November 2019
15 November 2019
Yogesh Puri, Vasanthakumar Gunasekaran, Shiva Kumar Palanisamy, Babu Elangovan, Pradeep Krishna, Balaji Balasubramanian, Anjana Ananth, Mettu Srinivas Reddy, Mohamed Rela – 14 November 2019
Josh Levitsky, Bryna E. Burrell, Sai Kanaparthi, Laurence A. Turka, Sunil Kurian, Alberto Sanchez‐Fueyo, Juan J. Lozano, Anthony Demetris, Andrew Lesniak, Allan D. Kirk, Linda Stempora, Guang‐Yu Yang, James M. Mathew – 13 November 2019
Tomasz Kostrzewski, Paloma Maraver, Larissa Ouro‐Gnao, Ana Levi, Sophie Snow, Alina Miedzik, Krista Rombouts, David Hughes – 13 November 2019 – Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD), which to date has no approved drug treatments. There is an urgent need for better understanding of the genetic and molecular pathways that underlie NAFLD/NASH, and currently available preclinical models, be they in vivo or in vitro, do not fully represent key aspects of the human disease state.
Digest a debrief of the newest data on the treatment of viral hepatitis presented at The Liver Meeting.
At the 2019 Leon Schiff State-of-the-Art Lecture, our selected speaker will provide a thorough overview of the advances in knowledge of the pathogenesis of hepatocellular carcinoma (HCC). The lecture will explore current data on evidence-based treatment of this disease, including novel molecular therapies and advances in precision oncology.
Review key highlights from all the exciting clinical research presented at The Liver Meeting® 2019.
Review a condensed summary of the clinical research highlights from The Liver Meeting.
Harriet Gaskell, Xiaodong Ge, Romain Desert, Sukanta Das, Hui Han, Daniel Lantvit, Grace Guzman, Natalia Nieto – 12 November 2019 – Nonalcoholic steatohepatitis (NASH) is a metabolic disorder in which poor nutrition and the gut‐to‐liver interaction play a major role. We previously established that hepatic high mobility group box‐1 (HMGB1) is involved in chronic liver disease. HMGB1 increases in patients with NASH and it is expressed in intestinal epithelial cells (IEC); yet, the role of intestinal HMGB1 in the pathogenesis of NASH has not been investigated.